6 hasil untuk "Cohn, Erica"
Menampilkan 1–6 · 1,22 detik · RSS
-
Artikel Jurnal Teks lengkap
Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa
IMPORTANCE: There is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS). OBJECTIVE: To compare efficacy, safety, and tolerability of treatments for moderate to severe HS. DATA SOURCES: MEDLINE, Embase, ClinicalTrials.gov, and Cochrane…
-
Artikel Jurnal Teks lengkap
Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies
PURPOSE: In patients with metastatic prostate cancer (MPC), the contribution of nonmalignant etiologies to morbidity is often overlooked. METHODS: We retrospectively reviewed the documented specialist assessments of back pain in men with MPC in a joint medical oncology and physiatry clinic at our…
-
Artikel Jurnal Teks lengkap
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer
INTRODUCTION: Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of life, and longer survival. Limited data exist on the benefit of this symptom…
-
Artikel Jurnal Teks lengkap
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
BACKGROUND: No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. OBJECTIVE: To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. DESIGN, SETTING, AND…
-
Artikel Jurnal Teks lengkap
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
BACKGROUND: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus prednisone (AAP) in BCR is unknown. OBJECTIVE: To…